Business
Rallybio to Present at Upcoming Investor Conferences
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into
About this update from Rallybio Corporation
[{"type":"text","content":" NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced its participation in the following upcoming investor conferences:\n\n\n\n2024 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 5, 2024. Stephen Uden, M.D., Chief Executive Officer, will participate in a fireside chat at 3:45 p.m. ET.\n\n\n\nH.C. Wainwright 26th Annual Global Investment Conference in New York, NY on Tuesday, September 10, 2024. Dr. Uden will present a corporate overview at 11:00 a.m. ET.\n\n\n\nLive webcasts of the Wells Fargo fireside chat and H.C. Wainwright presentation will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each presentation.\n\n\nAbout Rallybio\nRallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240826376744/en/\n\nInvestors\nSamantha Tracy\nRallybio Corporation\n(475) 47-RALLY (Ext. 282)\[email protected]\n\n\nKevin Lui\nPrecision AQ\n(212) 698-8691\[email protected]\n\n\nMedia\nVictoria Reynolds\nMission North\n(760) 579-2134\[email protected]\n\n\nSource: Rallybio Corporation","length":5337,"tagName":"div"}]